Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Title: An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)      
available:
True
dateReleased:
08-28-2013
description:
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder (ADHD).
privacy:
information not available
aggregation:
instance of dataset
ID:
NCT01933880
refinement:
curated
keywords:
Attention Deficit Hyperactivity Disorder
Methylphenidate Hydrochloride
CONCERTA
dateModified:
09-16-2014
availability:
available
types:
clinical trial
name:
Attention Deficit Hyperactivity Disorder (ADHD)
funders:
Xian-Janssen Pharmaceutical Ltd.
selectionCriteria:
Inclusion Criteria: - ADHD children must sign the consent form in person, and their parents or guardian must endorse, in the consent form, participation of the child in the designated research program - Through personal interaction and assessment questionnaire, examine to determine compliance of DSM-IV ADHD diagnostic criteria - According to the judgment of researchers, the ADHD children should have normal intelligence. Normal intelligence is defined as no obvious evidence of mental retardation in general (specific learning disabilities will not be considered mental retardation in general), formal IQ test to be conducted and 85 marks or above ought to be scored - ADHD children should not have been subjected to psychotropic drug treatment within 6 months. Those ADHD children on whom methylphenidate immediate-release tablets treatment is effective (with maximum daily dosage of 60 mg), may be admitted - Normal children with IQ greater than or equal to 85 Exclusion Criteria: - Unable to fully comply with the cognitive function test in the laboratory - Known to be allergic to methylphenidate - Consumption of psychoactive drugs currently or in the past 30 days, including use of monoamine oxidase inhibitors, clonidine, other alpha 2 adrenergic receptor agonists, tricyclic antidepressants, theophylline, bishydroxycoumarin etc - History of alcohol, drugs or substances abuse - Have medical history of type I or II bipolar affective disorder, anxiety disorder, schizophrenia or pervasive developmental disorder
studyGroups:
OROS-MPH Group
Normal Group
types:
Interventional
ID:
CR016078
accessURL: https://clinicaltrials.gov/ct2/show/results/NCT01933880
storedIn:
ClinicalTrial.gov
format:
HTML
accesstypes:
landing page
dateVerified:
20140901
authentication:
none
authorization:
none
creators:
Xian-Janssen Pharmaceutical Ltd.
homepage: https://clinicaltrials.gov
ID:
SCR:002309
name:
ClinicalTrials.gov

Feedback?

If you are having problems using our tools, or if you would just like to send us some feedback, please post your questions on GitHub.